Stealth Biotherapeutics Inc., of Boston, said its MMPOWER phase II trial evaluating the systemic delivery of elamipretide for the treatment of primary mitochondrial myopathy, or muscle weakness, in patients with a genetically confirmed mitochondrial disease yielded positive data.